Press Release 27th February 2002
Proteome Sciences plc ("Proteome Sciences"), the AIM listed
proteomics and modification of
gene expression company, announces that it has entered into a collaborative research agreement with ReNeuron Holdings plc ("ReNeuron") to identify
proteins expressed in
brain repair in response to
stroke as possible therapeutic entities or
drug targets relevant for the treatment of
stroke and other
neurodegenerative diseases at our facilities at King's College, London.
Proteome Sciences has already successfully applied its
proteomics research platform to search for a reliable diagnostic marker for stroke. Using high sensitivity
protein separation, Proteome Sciences has identified markers in
blood for the
diagnosis of stroke and which can also differentiate between stroke and
heart attack. The research is currently focused on the differentiation between ischaemic and haemorragic stroke. Discussions are actively in progress with strategic
licensing partners for commercialisation.
The collaboration with ReNeuron will extend Proteome Sciences' programme in stroke to address further drug targets and potential therapeutic entities. The companies will jointly own intellectual property arising from the collaboration and share any resulting revenues from its commercialisation.